17. Jahreskongress für Klinische Pharmakologie
Verbund Klinische Pharmakologie in Deutschland
01. - 02. Oktober 2015, Köln
Abstracts
Invited Lecture
(15vklipha01)
[Full Text]
Novel polypharmacological approaches for the treatment of the metabolic syndrome
Müller TD[Full Text]
Invited Lecture
(15vklipha03)
[Full Text]
HCV Infektion – Gesundheitsökonomische Aspekte als Teil der Behandlungsindikation
Rossol S[Full Text]
Invited Lecture
(15vklipha04)
[Full Text]
Klinische Prüfung – praktische Aspekte bei der Umsetzung der EU Regulation 536/2014 aus Sicht der pharmazeutischen Industrie
Ruppert T[Full Text]
Poster Abstract
(15vklipha05)
[Full Text]
Cellular uptake of sorafenib is independent of major human organic cation and organic anion uptake transporters of the hepatocyte
Neul C, Schaeffeler E, Laufer S, Schwab M, Nies A[Full Text]
Poster Abstract
(15vklipha06)
[Full Text]
Pharmacological data on Valerian, Melissa and Passion flower extracts and their combination point to a synergistic effect
Okpanyi SN, Abdel-Aziz H, Kelber O[Full Text]
Poster Abstract
(15vklipha07)
[Full Text]
The 50-50-50 Rule for Dosing of Psychoactive Drugs in the Elderly
Keller F[Full Text]
Poster Abstract
(15vklipha08)
[Full Text]
Assessment of Inhibitory Effects on Major Human Cytochrome P450 Enzymes by Spasmolytics Using a Seven-in-One In Vitro Assay
Dahlinger D, Frechen S, Aslan S, Fuhr U[Full Text]
Poster Abstract
(15vklipha09)
[Full Text]
Monitoring of azathioprine metabolite concentrations in autoimmune hepatitis
Züst A, Jetter A[Full Text]
Poster Abstract
(15vklipha10)
[Full Text]
Microdialysis as a promising new method to assess the ocular pharmacokinetics of topical eye drops in a rabbit animal model
Garhöfer G, Klaus R, Jäger W, Zeitlinger M, Schmetterer L[Full Text]
Poster Abstract
(15vklipha11)
[Full Text]
A twin study using unlabelled 12C and labeled 13C caffeine orally revealing common environmental effects on CYP1A2 activity but almost no heritability of CYP1A2 activity
Matthaei J, Schwab M, Kerb R, Hofmann U, Sehrt D, Sachse-Seeboth C, Strube J, Brockmöller J[Full Text]
Poster Abstract
(15vklipha12)
[Full Text]
Adenosine receptors in inflammation on rat colon preparations. Are they involved in the anti-inflammatory action of STW 5?
Nieber K, Voß U, Müller C, Abdel-Aziz H, Kelber O[Full Text]
Poster Abstract
(15vklipha13)
[Full Text]
Azathioprine-induced pancreatitis in myasthenia gravis with certain causality: case report
Grabowski K, Douros A, Bronder E, Klimpel A, Garbe E, Kreutz R[Full Text]
Poster Abstract
(15vklipha14)
[Full Text]
Comprehensive Metabolomic and Lipidomic Profiling of Clear Cell Renal Cell Carcinoma and Therapeutic Consequences
Leuthold P, Schaeffeler E, Hofmann U, Mürdter T, Rausch S, Bedke J, Schwab M, Haag M[Full Text]
Poster Abstract
(15vklipha15)
[Full Text]
Co-prescription of QT-interval prolonging drugs: an analysis in a large cohort of geriatric patients
Schächtele S, Tümena T, Gaßmann KG, Fromm MF, Maas R[Full Text]
Poster Abstract
(15vklipha16)
[Full Text]
Effects of STW 5, STW 5-II and STW 6 on rat ileal and colonic preparations: Region specific effects
Nieber K, Voß U, Abdel-Aziz H, Okpanyi S, Kelber O[Full Text]
Poster Abstract
(15vklipha17)
[Full Text]
Pharmacokinetics of ketamine prolonged release tablets in healthy subjects
Roustom T, Modess C, Mahmoud H, Oswald S, Burger N, Siegmund W[Full Text]
Poster Abstract
(15vklipha18)
[Full Text]
Population pharmacokinetics of iohexol in elderly people
Taubert M, Schäffner E, Ebert N, van der Giet M, Martus P, Jakob O, Fuhr U[Full Text]
Poster Abstract
(15vklipha19)
[Full Text]
Protein abundance of clinically relevant metabolizing enzymes along the human intestine
Busch D, Gröer C, Busemann A, Partecke LI, Heidecke CD, Siegmund W, Oswald S[Full Text]
Poster Abstract
(15vklipha20)
[Full Text]
Quantitative chiral and achiral determination of ketamine and its metabolite in human serum, urine and feces
Hasan M, Siegmund W, Oswald S[Full Text]
Poster Abstract
(15vklipha21)
[Full Text]
Uptake of MPP+, metformin and several other drugs by MATE1, MATE2K
Hong H, Fuhr U, Gründemann D[Full Text]
Invited Lecture
(15vklipha22)
[Full Text]
Bewertung neuer Antikoagulantien unter Berücksichtigung von Biomonitoring und Antidots
Greinacher A[Full Text]
Invited Lecture
(15vklipha23)
[Full Text]
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz R, Schlüter KD[Full Text]
Invited Lecture
(15vklipha24)
[Full Text]
Scientific Advice in Europe provided by EMA and National Agencies
Laslop A[Full Text]
Invited Lecture
(15vklipha25)
[Full Text]
Teaming up for value? Erste Erfahrungen aus dem "Early Dialogue“ zwischen Herstellern und Zahlern.
Zebedin-Brandl E, Warmuth M, Sauermann R[Full Text]
Invited Lecture
(15vklipha26)
[Full Text]
Therapie-Adhärenz – mehr als nur ein Schlagwort?
Matthes J[Full Text]
Invited Lecture
(15vklipha27)
[Full Text]
Therapieadhärenz – Verbesserungsmöglichkeiten auf der Wirkstoffseite (PK/PD)
Wehling M[Full Text]
Invited Lecture
(15vklipha28)
[Full Text]
Physician-patient communication and drug therapy safety – the importance of comprehensible product information
Stetter E[Full Text]
Invited Lecture
(15vklipha29)
[Full Text]
Fifteen years of drug development for patients with Multiple Sclerosis – adherence and compliance, what has been achieved?
Jahn S, Hamburg H, Pring-Åkerblom P[Full Text]
Invited Lecture
(15vklipha30)
[Full Text]
Translational Strategies and Data Packages for Early Clinical Trials
Zuehlsdorf M[Full Text]
Invited Lecture
(15vklipha31)
[Full Text]
(R)evolution of early phase clinical trials in oncology
Mikus G[Full Text]
Invited Lecture
(15vklipha32)
[Full Text]
Der Medikationsplan in der Modellregion Erfurt
Thürmann P, Brell D, Fenske D[Full Text]
Invited Lecture
(15vklipha33)
[Full Text]
MetropolMediplan 2016 – MMP16 Evaluation of the acceptance and practicability of the German federal medication list in the metropolitan region Nuremberg-Fürth-Erlangen
Maas R, Friedland K, Bangemann M, Jobst F, Prokosch HU, Zerth J, Hellmann G, Dörje F, Schlenk M, Röck C, Steidl R, Fromm M, Dormann H[Full Text]
Invited Lecture
(15vklipha34)
[Full Text]
The project PRIMA – Primärsystem-Integration des Medikationsplans mit Akzeptanzuntersuchung
Strunz AK, Eickhoff C, Botermann L, Felberg M, Müller U, Schulz M[Full Text]
Invited Lecture
(15vklipha35)
[Full Text]
Pathophysiology and current therapy of age-related macular degeneration (AMD)
Kunert KS[Full Text]
Invited Lecture
(15vklipha36)
[Full Text]
Pathophysiology and current medical therapy of open angle glaucoma
Kunert KS[Full Text]
Invited Lecture
(15vklipha37)
[Full Text]
New galenical approaches to reach the anterior segment of the eye: oily emulsions, implants etc.
Schug B[Full Text]
Invited Lecture
(15vklipha38)
[Full Text]
Die Sicht der Ethikkommission mit Schwerpunkt Medikamente
Brunner M[Full Text]
Invited Lecture
(15vklipha39)
[Full Text]
Medizinprodukte – Definitionen, Klinische Prüfung
Seiter S[Full Text]
Invited Lecture
(15vklipha40)
[Full Text]
Food supplements classification – clinical trial of products – efficacy – advertising
Breitweg-Lehmann E[Full Text]
Invited Lecture
(15vklipha41)
[Full Text]
Pharmacogenomics and individualized therapy – the regulator's science
Stingl J[Full Text]
Invited Lecture
(15vklipha42)
[Full Text]
PET-optimized pharmacotherapy of central nervous system disorders
Bauer M[Full Text]
Invited Lecture
(15vklipha43)
[Full Text]
Gadoxetate, a MRI-contrast agent to measure individual functions of hepatic drug transporters?
Siegmund W[Full Text]
Invited Lecture
(15vklipha44)
[Full Text]
Endometriosis – Challenges in Pharmacotherapy of a little-noticed disease
Rhode B[Full Text]
Oral Abstract
(15vklipha45)
[Full Text]
Multi-step evaluation of data on the multi-target effect of STW 5
Lorkowski G, Kelber O, Abdel-Aziz H, Okpanyi SN, Storr M, Nieber K[Full Text]
Oral Abstract
(15vklipha46)
[Full Text]
Readability of informed-consent forms in UK, Germany, Austria and Switzerland
Lagler FB, Weineck SB, Schwab M[Full Text]
Invited Lecture
(15vklipha47)
[Full Text]
Pharmakologische Behandlung der Altersdepression
Holthoff-Detto V[Full Text]
